Activity

Ivermectin is an antiparasitic drug used to treat blindness caused by rivers, is being prescribed off-label to treat COVID-19 in a few regions of the world however, regulators are recommending randomized controlled trials be conducted before widespread use is adopted.

Researchers have demonstrated that ivermectin may inhibit SARS-CoV-2 in cell cultures and sparked a wave of excitement to use the drug for antiviral use at a time when few alternatives were available. Even though the concentration of ivermectin in vitro was significantly higher than physiological levels in human clinical applications, the favorable findings were quickly circulated and were later referenced in over 450 publications.

Ivermectin is a COVID-19 treatment

Citing the findings of this study, some physicians are beginning to incorporate the off-label use of
Ivermectin into their COVID-19 treatment plans. While the medication is safe, scientists worry that doctors are prescribing it to treat COVID-19.

The pandemic creates the feeling of urgency and it is common to cut corners, which is fine however, you shouldn’t cut every corner. Scientific rigor is essential. Many people might ask, "What do I have to lose?" It’s a drug that is safe,’ but no drug is free from side effects.

The mechanism through which Ivermectin works as an antiviral remains unclear, it has also inhibited viral replication in other RNA viruses, such as dengue virus as well as Zika virus. You can find details info about ivermectin , as well as a COvid-19 vaccine from Docile Britain.

Ivermectin may cause stomach side effects and skin rash. In rare instances it could also be neurotoxic. FDA posted May 1, 2012 that the FDA cautioned against the use of Ivermectin for the treatment or prevention of COVID-19 if there are no clinical studies.

Positive Sign Of Ivermectin

After witnessing the promising results of the April in vitro study, people started to use ivermectin in COVID-19 treatment in critical patients. In the beginning, dexamethasone, remdesivir, and convalescent plasma were not on the market or were inaccessible because not enough people were recovering.

Rajter claimed that he was able to treat fifteen patients using normal doses of ivermectin to treat scabies in the second quarter of April. The treatment had a high success rate.

Ivermectin’s benefits

Ivermectin’s survival benefits in patients with severe COVID-19 was determined to be greater than the usual care in the study with no peer review. The association remained after adjusting for the differences among groups, such as the treatment with azithromycin, hydroxychloroquine, and zinc, which was common.

The article was published in a the form of a preprint, and other researchers across the world were interested. The story of success we shared in April of this year has been duplicated in other smaller studies across the world. It’s hard to interpretsince the majority of patients suffering from COVID-19 recover on their own.